Stoke Therapeutics Inc
NASDAQ:STOK

Watchlist Manager
Stoke Therapeutics Inc Logo
Stoke Therapeutics Inc
NASDAQ:STOK
Watchlist
Price: 9 USD 4.65% Market Closed
Market Cap: 476.7m USD

EV/EBITDA
Enterprise Value to EBITDA

-2.1
Current
-2.5
Median
3.9
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-2.1
=
Enterprise Value
237.3m USD
/
EBITDA
-115m USD
EBITDA Growth EV/EBITDA to Growth
US
Stoke Therapeutics Inc
NASDAQ:STOK
Average EV/EBITDA: 60.8
Negative Multiple: -2.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 674.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.4
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.7
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
11.4
6%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27
16%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -538.8 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
12%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.2
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.6 N/A N/A
NL
argenx SE
XBRU:ARGX
324.7
168%
1.9

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-2
2-Years Forward
EV/EBITDA
-1.7
3-Years Forward
EV/EBITDA
-1.5